Sun Pharmaceutical Industries Ltd announced a $25 million investment in US-based Pharmazz Inc, increasing its stake to 22.7%. The investment includes conversion of an earlier SAFE agreement at a discounted price. $10 million and $7.5 million from the second SAFE tranche will be infused by May 31, 2025, with the remaining $15 million by November 30, 2025. Sun Pharma holds exclusive rights to license and distribute Sovateltide in emerging markets and may negotiate licensing in developed countries. Pharmazz, focused on Sovateltide (for stroke) and Centhaquine (for shock), plans global Phase-3 trials after FDA approval.